RNAZ (TransCode Therapeutics, Inc.) Volume dana dhuwit perusahaan

Logo grafis TransCode Therapeutics Inc. (RNAZ)

TransCode Therapeutics (RNAZ) focuses on preclinical tests of its proprietary DNA platform, limiting itself to grant agreements. The company attracts biochemists through stock option programs and research freedom. Robotic systems accelerate trials, minimizing errors in drug delivery. The free cash flow level demonstrates capital dynamics, while the value of 0.01 shows the organization's latest liquid reserve value.

Total volume dana dhuwit perusahaan: TransCode Therapeutics (RNAZ) kanggo 04.07.2022 - 21.11.2026

Rincian analitis perusahaan TransCode Therapeutics

- nilai saham lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
Ringkesan analisis perusahaan:transcodetherapeutics.com
Sampel barang transcodetherapeutics.com

TransCode Therapeutics (RNAZ) operates in a preclinical research phase without generating revenue. This metric accumulates liquid asset balances to determine the startup's financial autonomy, measuring the company's ability to cover rising RNA drug development costs without emergency capital raises. While a high cash reserve prevents liquidity gaps, it carries the risk of inflationary depreciation. The dynamics of these reserves are clearly reflected in the free cash flow figure.

Pesaing utama

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|PRME (Prime Medicine Inc) - Volume dana dhuwit perusahaan|Taysha Gene Therapies (TSHA) - Aset likuid perusahaan|Dhuwit awis perusahaan QURE (uniqure.com)|Gunggung dana dhuwit perusahaan MGTX|Volume dana dhuwit perusahaan RGNX (regenxbio.com)|SLDB: Dhuwit awis lan setara dhuwit awis perusahaan|ocugen.com - Volume dana dhuwit perusahaan|PACB - Volume dana dhuwit perusahaan|BNTC: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan DSGN|Dana dhuwit perusahaan Rocket Pharmaceuticals|Dhuwit awis perusahaan 4DMT (FDMT)|Volume dana dhuwit perusahaan LXEO|Aset likuid perusahaan Korro Bio Inc.|Volume dana dhuwit perusahaan EDIT (Editas Medicine Inc)|SLN: Dhuwit awis lan setara dhuwit awis perusahaan|PRQR - Dana dhuwit perusahaan|Aset likuid perusahaan codexis.com CDXS|SGMO: Volume dana dhuwit perusahaan|Nautilus Biotechnology (NAUT) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan Metagenomi, Inc|precisionbiosciences.com (DTIL) - Aset likuid perusahaan|Dana dhuwit perusahaan Generation Bio Co. (GBIO)|Aset likuid perusahaan Boundless Bio, Inc.|Dana dhuwit perusahaan Exicure, Inc. XCUR|IMNN: Dhuwit awis lan setara dhuwit awis perusahaan|PHIO - Dana dhuwit perusahaan|Aset likuid perusahaan Mustang Bio MBIO|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan